Cell Therapies, Cancer & Rare Diseases

Cell Therapies, Cancer & Rare Diseases
  • Pininvest Analysis

Cell therapies have opened new treatment fields by cell inhibitors, gene modification, or even gene replacement

By gene modification after extraction of white blood cells from a leukemia-fighting patient, the cells are bolstered for more vigorous attack of cancer cells and reinjected in the patient; the Novartis treatment researched by University of Pennsylvania has been approved by the FDA in August ’17 and more than 76 applications have been accepted for testing in this promising field, possibly extending the procedure to some forms of brain and lung cancer patients - Check our note "Immunotherapy by adaptive cell transfer (ACT)' for more information

Gene replacement aims disease caused by a single faulty gene and the first treatment, targeting vision loss due to genetic mutation, introduced by Spark Therapeutics, is the first of its kind to be approved by FDA (December ’17)

Read our notes

Cell Therapies, Cancer & Rare Diseases • Updated:

Name Ticker Exchange Sector Industry Currency Cur.Price Mkt.Cap Perf. Momentum Vol. Risk Contrib. MDD
 
Adaptimmune Therapeutics ADAP NASDAQ Health Care Biopharmaceuticals USD 5.04 782 M 52.7% Neutral 118%   5% -67%
Amgen AMGN NASDAQ Health Care Biopharmaceuticals USD 249.62 145 B 14.7% Weak Up 26%   1% -16%
Bellicum Pharmaceuticals BLCM NASDAQ Health Care Biopharmaceuticals USD 3.51 18 M -44.7% Sharp Down 107%   5% -70%
bluebird bio, Inc. BLUE NASDAQ Health Care Biopharmaceuticals USD 29.54 2.0 B -37.6% Sharp Down 74%   3% -64%
Cellectis (ADR) CLLS NASDAQ Health Care Gene Editing - Cell Therapies USD 19.51 829 M 79.2% Sharp Down 88%   6% -45%
Celyad (ADR) CYAD NASDAQ Health Care Biopharmaceuticals USD 6.95 97 M -22.8% Weak Down 57%   1% -45%
Clovis Oncology, Inc. CLVS NASDAQ Health Care Biopharmaceuticals USD 6.25 552 M -13.3% Neutral 96%   5% -57%
Corvus Pharmaceuticals CRVS NASDAQ Health Care Biopharmaceuticals USD 2.83 79 M 21.5% Sharp Down 101%   4% -49%
CRISPR Therapeutics CRSP NASDAQ Health Care Gene Editing - Cell Therapies USD 123.11 8.7 B 155.8% Sharp Down 64%   5% -47%
Editas Medicine EDIT NASDAQ Health Care Gene Editing - Cell Therapies USD 41.53 2.6 B 84.3% Sharp Down 86%   6% -56%
Gilead Sciences GILD NASDAQ Health Care Biopharmaceuticals USD 65.30 82 B -8.8% Neutral 28%   1% -30%
Immunogen IMGN NASDAQ Health Care Biopharmaceuticals USD 7.62 1.4 B 122.2% Weak Down 75%   4% -32%
Intellia Therapeutics NTLA NASDAQ Health Care Gene Editing - Cell Therapies USD 76.35 4.5 B 493.7% Weak Up 87%   7% -44%
Intercept Pharmaceuticals ICPT NASDAQ Health Care Biopharmaceuticals USD 21.41 706 M -70.2% Neutral 88%   4% -79%
Invitae NVTA NYSE Health Care Gene Editing - Cell Therapies USD 39.07 6.9 B 188.1% Sharp Down 83%   5% -42%
MacroGenics MGNX NASDAQ Health Care Biopharmaceuticals USD 31.28 1.8 B 464.6% Strong Up 141%   5% -40%
NantKwest, Inc. NK NASDAQ Health Care Biopharmaceuticals USD 32.49 3.5 B 887.5% Neutral 124%   7% -39%
Neos Therapeutics NEOS NASDAQ Health Care Drug Manufacturers -Specialty Pharma USD 1.15 57 M 21.1% Weak Up 100%   3% -53%
Novartis (ADR) NVS NYSE Health Care Drug Manufacturers - Diversified USD 86.75 196 B 5.3% Neutral 20%   1% -14%
Regeneron Pharmaceuticals REGN NASDAQ Health Care Biopharmaceuticals USD 481.16 51 B -6.0% Neutral 35%   1% -32%
REGENXBIO RGNX NASDAQ Health Care Gene Editing - Cell Therapies USD 35.34 1.3 B 10.6% Sharp Down 58%   4% -39%
Sangamo Therapeutics SGMO NASDAQ Health Care Gene Editing - Cell Therapies USD 11.64 1.6 B 59.9% Neutral 80%   5% -40%
uniQure QURE NASDAQ Health Care Gene Editing - Cell Therapies USD 34.88 1.6 B -33.5% Neutral 59%   3% -57%
Vericel VCEL NASDAQ Health Care Gene Editing - Cell Therapies USD 57.06 2.6 B 415.4% Strong Up 54%   3% -21%
ZIOPHARM Oncology ZIOP NASDAQ Health Care Biopharmaceuticals USD 3.45 739 M 27.3% Sharp Down 81%   5% -42%